← Leaderboards
Arbelo Cristina
Idt Biologika Gmbh
$2,723,700
Attributed
$2,723,700
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2019–21$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
Funding mix
By agency
NIH$2,723,700 · 1
By mechanism
N01$2,723,700 · 1
Top collaborators
No co-investigators on record.
Most similar at Idt Biologika Gmbh
Same institution · by research overlap
- Andreas Neubert$4,330,013
- Heidi Trusheim$2,688,800
- Suneel Singh$4,154,750
Others in their field
Other Emerging Leaders on “Adjuvant”
- Ted Ross · University Of Georgia$68,763,143
- Jay Evans · University Of Montana$43,101,450
- Valerie Fremont · Quality Biological, Inc.$19,261,930
- Aaron Esser-Kahn · University Of Chicago$13,698,058
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Garcia-Sastre Adolfo · Icahn School Of Medicine At Mount Sinai$8,560,974
Research focus
AdjuvantAttenuatedBiologicalBioterrorismClinical ResearchCommunicable DiseasesContractsCyclic GmpDevelopment PlansEmerging Communicable DiseasesNovel VaccinesProduct DevelopmentRespiratory Syncytial Virus VaccinesScale UpServicesUnited States Food And Drug AdministrationVaccine DeliveryVaccine DevelopmentVaccinesVero Cells
Grant awards (2)
Task V08: Process Development for Scale-up of Vero Cells on Micro-Carriers for Manufacturing of a Live-Attenuated RSV Vaccine$67,500
N01 · FY2021 · AI · contact PI
Task V08: Process Development for Scale-up of Vero Cells on Micro-Carriers for Manufacturing of a Live-Attenuated RSV Vaccine$2,656,200
N01 · FY2019 · AI · contact PI